**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 59250

**Manuscript Type:** ORIGINAL ARTICLE

***Case Control Study***

**Osteoprotegerin, interleukin and hepatocyte growth factor for prediction of diabetes and hypertension in the third trimester of pregnancy**

Huang SJ *et al*. Gestational diabetes complicated with hypertension

Su-Jing Huang, Hong-Wei Wang, Hai-Fang Wu, Qiu-Yuan Wei, Shu Luo, Lin Xu, Hong-Qiong Guan

**Su-Jing Huang, Hong-Wei Wang, Hai-Fang Wu, Qiu-Yuan Wei, Shu Luo, Lin Xu, Hong-Qiong Guan,** Department of Obstetrics, The Second Affiliated Hospital of Hainan Medical College, Haikou 570311, Hainan Province, China

**Author contributions:** Huang SJ and Wang HW contributed equally to this manuscript; Huang SJ, Wang HW, Wu HF, Wei QY, Luo S, Xu L and Guan HQ collected data and wrote the manuscript; Guan HQ reviewed the manuscript.

**Supported by** Hainan Province Major Program of Science and Technology Projects 2017, No. ZDKJ2017007.

**Corresponding author: Hong-Qiong Guan, MD, Chief Physician,** Department of Obstetrics, The Second Affiliated Hospital of Hainan Medical College, No. 48 Baishuitang Road, Haikou 570311, Hainan Province, China. guanhq1962@163.com

**Received:** September 1, 2020

**Revised:** September 24, 2020

**Accepted:** October 1, 2020

**Published online:** November 26, 2020

**Abstract**

BACKGROUND

Gestational diabetes mellitus (GDM) raises the risk of high blood pressure and may cause a series of life-threatening complications in pregnant women. Screening and management of GDM and gestational hypertension (GH) in pregnancy helps to control and reduce these risks and prevent adverse effects on mothers and their fetuses. Currently, the majority criteria used for screening of diabetes mellitus is oral glucose tolerance tests, and blood pressure test is usually used for the screening and diagnosis of hypertension. However, these criteria might not anticipate or detect all GDM or GH cases. Therefore, new specific predictive and diagnostic tools should be evaluated for this population. This study selected three biomarkers of osteoprotegerin (OPG), interleukin (IL) and hepatocyte growth factor (HGF) for GDM and GH predication and diagnosis.

AIM

To explore the feasibility of changes in placentaland serum OPG, IL and HGF as tools for prediction and diagnosis of diabetes and hypertension in pregnant women.

METHODS

From January 2018 to January 2019, 44 pregnant women with GDM and GH were selected as an observation group, and 44 healthy pregnant women were selected as a control group in the same period. Serum OPG, IL and HGF were compared between the two groups.

RESULTS

The levels of OPG and HGF in the observation group were lower than in the control group, and the level of IL-1β was higher in the observation group than in the control group (all *P* < 0.05). Furthermore, OPG and HGF were negatively associated with gestational diabetes and gestational hypertension, while IL-1β was positively associated with GDM complicated with GH (all *P* < 0.05).

CONCLUSION

The evaluation of serum OPG, HGF and IL-1β levels in patients with coexistent gestational diabetes complicated with hypertension can predict the degree of disease and play an important role in the follow-up treatment and prognosis prediction.

**Key Words:** Third trimester of pregnancy; Osteoprotegerin; Interleukin; Hepatocyte growth factor; Gestational diabetes mellitus; Gestational hypertension

**Citation:** Huang SJ, Wang HW, Wu HF, Wei QY, Luo S, Xu L, Guan HQ. Osteoprotegerin, interleukin and hepatocyte growth factor for prediction of diabetes and hypertension in the third trimester of pregnancy. *World J Clin Cases* 2020; 8(22): 5529-5534

**URL:** https://www.wjgnet.com/2307-8960/full/v8/i22/5529.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v8.i22.5529

**Core Tip:** Gestational diabetes mellitus (GDM) and gestational hypertension (GH) are associated with serious and long-term feto-maternal and neonatal outcomes compared to normal pregnancies. Although oral glucose tolerance tests and blood pressure tests were accepted criteria for screenings of GDM and GH, these criteria might not anticipate or detect all GDM or GH cases. Biomarkers may serve as adjunct predictors for GDM and GH. The present study explored osteoprotegerin, interleukin and hepatocyte growth factor for prediction of GDM and GH.

**INTRODUCTION**

Gestational diabetes mellitus (GDM) is a disease associated with impaired glucose tolerance and glucose intolerance during pregnancy[1-2]. Studies[3-6] showed that the incidence of GDM was 1% to 5%. The onset and development of GDM is usually caused by overnutrition, rapid weight gain and lack of exercise during the pregnancy. In the clinical practice, the incidence of GDM has increased in recent years. Moreover, 30% of women with GDM have a higher risk of gestational hypertension (GH), and the risk is three to five times than the pregnant women without GDM. These two diseases have a great impact on the prognosis of fetuses and the mothers. Pathogenic factors for GDM are complex. Some studies[7-10] pointed out marker levels including osteoprotegerin (OPG), interleukin-1β (IL-1β) and hepatocyte growth factor (HGF) may be factors in predicting the severity of a disease. Early detection of changes in a patient’s condition can help to reduce the incidence of hypertension and improve the outcomes of pregnancy. The present study explored the significance of detection of OPG, IL-1β and HGF in the placenta and serum in evaluating and predicting the onset and development of gestational diabetes and hypertension in the third trimester of pregnancy.

**MATERIALS AND METHODS**

***Participants***

A total of 44 pregnant women with GDM and GH were selected as an observation group from January 2017 to December 2018. Another 44 healthy pregnant women were selected as a control group. Eligibility criteria[11-13] for participants included: participants in the observation group were diagnosed with GDM and GH in accordance with diagnostic code; the present study was approved by the ethics committee of our hospital; patient adherence to therapy was high and therefore the subsequent research was conducted successfully; and no other diseases occurred influencing the development of the study. Patients with immune disorders or mental illness and patients who used drugs that affect lipid metabolism recently were considered ineligible. The average age was 28 to 39 years (34.5 ± 1.8) in the observation group and 27 to 36 years (33.2 ± 1.9) in the control group. There was no significant difference in patient information between the two groups (*P* > 0.05).

***Methods***

Five milliliters of blood were drawn from each of the participants. The collected samples were centrifuged at 3500 r/min for 10 min. Then the supernatants were kept at -80 °C for testing. Enzyme linked immunosorbent assay was used to test the levels of serum OPG and IL-1β with reagents from Beijing Derman International Freight Forwarding Co., Ltd., which were produced by Biomedica, Wien, Österreich, Austria. HGF was tested using immunohistochemistry. All the procedures were performed strictly based on the kit instructions.

***Measurements***

Levels of OPG, IL-1β and HGF were compared between the two groups.

***Statistical analysis***

SPSS18.0 and Student’s *t* test were used to process data in the study. Quantitative data was expressed as mean ± standard deviation, and dichotomous data was expressed as percentage. *P* < 0.05 indicated that the difference was statistically significant.

**RESULTS**

***Levels of OPG, IL-1β and HGF***

Levels of OPG and HGF were lower in the observation group than in the control group (*P* < 0.05). However, levels of IL-1β were higher in the observation group than in the control group (*P* < 0.05, Table 1).

***Relationship between GDM and GH and OPG, IL-1β and HGF***

OPG and HGF were negatively associated with GDM and GH, and IL-1β was positively associated with GDM and GH (all *P* < 0.05, Table 2).

**DISCUSSION**

The incidence of GDM is increasing worldwide in recent years. It may range from 1% to 14% in the world and 1% to 5% in China. The causes of GDM are complex. One of the common complications is macrosomia followed by abortion, shoulder dystocia, laceration of birth canal, *etc*. Moreover, GDM may lead directly to fetal overgrowth and puts offspring at high risk of diabetes during pregnancy[14,15]. Several studies[16-18] revealed that the incidence ofGH increases in the above population. The incidence of eclampsia, serious eclampsia and pre-eclampsia is 3.9%, 4.5% and 4.4%, respectively. GH has a great effect on maternal and child health and is a common reason accounting for the increasing maternal and perinatal mortality. Accordingly, early diagnosis and treatment can help to improve the prognosis and reduce the incidence of complications.

OPG functioning as a soluble decoy receptor is a member of the tumor necrosis factor family. In pregnant women with GDM, changes in the levels of OPG may be associated with insulin levels and obesity. Cytokine-induced OPG can help to protect pancreatic β cells from being further injured. Additionally, Bogdanet *et al*[19] confirmed that changes in the levels of OPG may have an impact on vascular endothelial function and the development of complications. Thereby, OPG is an important indictor in predicting cardiovascular events.

IL-1β plays a significant role in the progression of pancreatic inflammation. Animal testing showed that apoptosis in pancreatic β cells occurred when they were exposed to IL-1β. Furthermore, Anderlová *et al*[20] reported that IL-1β is an important factor influencing endothelial cell injury. It is the central tache for hypertension and also for GH.

HGF is an essential human cytokine that is mainly produced by placental tissues. HGF increases vasodilation in the microvascular circulation, resists pancreatic β proliferation and decreases blood glucose. It may play an important role in the prevention of GH in pregnant women with GDM.

The present study found that there was significant differences in the levels of OPG, HGF and IL-1β between healthy pregnant women and pregnant women with GDM complicated with GH (all *P* < 0.05). OPG and HGF were negatively associated with and IL-1β was positively associated with the incidence of GDM and GH in pregnant women. Studies showed that OPG, HGF and IL-1β were important cytokines and inflammatory factors that are actively involved in the development of GDM and GH. Detection of the above indicators can provide an important basis for the treatment decision and prognosis prediction.

**CONCLUSION**

In general, detection of OPG, HGF and IL-1β levels can help to predict severity of gestational diabetes and hypertension in pregnant women, which plays an important role in treatment selection and prognosis prediction.

**ARTICLE HIGHLIGHTS**

***Research background***

Gestational diabetes mellitus (GDM) and gestational hypertension (GH) exerts serious effects on the health of perinatal pregnant women and fetuses. Clinical screening of GDM and GH may attenuate the associated disorders in women and offspring. Currently, GDM diagnosis is based on evaluation of glucose tolerance tests at late stages of pregnancy but increased age, body weight and history of GDM may conditionate this criterion. For instance, it was found that using fasting plasma glucose criteria alone, more GDM diagnoses were missed in women ≥ 35 years than in women < 35 years. A simple and effective way is needed to predict GDM and GH in this population.

***Research motivation***

Interleukin-1β (IL-1β) has been implicated as a key proinflammatory cytokine involved in the pancreatic islet inflammation of diabetes mellitus. Hepatocyte growth factor (HGF) plays a central role in metabolic disorders and contributes to insulin resistance and diabetes pathophysiology. Osteoprotegerin (OPG) is a soluble glycoprotein and is involved in different metabolic alterations such as diabetes, obesity, hypertension and metabolic syndrome. Thus, levels of IL-1β, HGF and OPG could be selected as biomarkers for disease status and progression of GDM and GH in pregnant women.

***Research objectives***

The aim of this study was to explore the efficacy of detection of placental and serum OPG, IL-1β and HGF for prediction and diagnosis of diabetes and hypertension in pregnant women.

***Research methods***

In total, 44 pregnant women with GDM and GH were selected as an observation group, and 44 healthy pregnant women were selected as a control group in the same period. OPG, IL-1β and HGF were compared between the two groups.

***Research results***

The levels of OPG and HGF in the observation group were lower than in the control group, and the level of IL-1β was higher in the observation group than in the control group. Furthermore, OPG and HGF were negatively associated with GDM and GH, while IL-1β was positively associated with GDM complicated with GH.

***Research conclusions***

The evaluation of serum OPG, HGF and IL-1β levels in patients with coexistent gestational diabetes complicated with hypertension can predict the degree of disease and play an important role in the follow-up treatment and prognosis prediction.

***Research perspectives***

More clinical and validation studies should be conducted to further evaluate the performance of biomarkers of OPG, IL-1β and HGF for GDM and GH predication and diagnosis including sensitivity, specificity and accuracy before potential use of these biomarkers as predictors in clinical practice.

**REFERENCES**

1 **Romano ME**, Gallagher LG, Jackson BP, Baker E, Karagas MR. Maternal urinary cadmium, glucose intolerance and gestational diabetes in the New Hampshire Birth Cohort Study. *Environ Res* 2019; **179**: 108733 [PMID: 31561054 DOI: 10.1016/j.envres.2019.108733]

2 **Absalom G**, Zinga J, Margerison C, van der Pligt P. Associations of dietetic management with maternal and neonatal health outcomes in women diagnosed with gestational diabetes: a retrospective cohort study. *J Hum Nutr Diet* 2019; **32**: 728-736 [PMID: 31322776 DOI: 10.1111/jhn.12682]

3 **Hetkamp T**, Hammer K, Möllers M, Köster HA, Falkenberg MK, Kerschke L, Braun J, Oelmeier de Murcia K, Klockenbusch W, Schmitz R. Fetal adrenal gland size in gestational diabetes mellitus. *J Perinat Med* 2019; **47**: 941-946 [PMID: 31562804 DOI: 10.1515/jpm-2019-0146]

4 **Lu X**, Wu F, Jiang M, Sun X, Tian G. Curcumin ameliorates gestational diabetes in mice partly through activating AMPK. *Pharm Biol* 2019; **57**: 250-254 [PMID: 30957612 DOI: 10.1080/13880209.2019.1594311]

5 **Zhao H**, Tao S. MiRNA-221 protects islet β cell function in gestational diabetes mellitus by targeting PAK1. *Biochem Biophys Res Commun* 2019; **520**: 218-224 [PMID: 31587871 DOI: 10.1016/j.bbrc.2019.09.139]

6 **Akbas M**, Koyuncu FM, Oludag Mete T, Taneli F, Ozdemir H, Yilmaz O. Serum levels of spexin are increased in the third trimester pregnancy with gestational diabetes mellitus. *Gynecol Endocrinol* 2019; **35**: 1050-1053 [PMID: 31109216 DOI: 10.1080/09513590.2019.1616690]

7 **Sauder KA**, Bekelman TA, Harrall KK, Glueck DH, Dabelea D. Gestational diabetes exposure and adiposity outcomes in childhood and adolescence: An analysis of effect modification by breastfeeding, diet quality, and physical activity in the EPOCH study. *Pediatr Obes* 2019; **14**: e12562 [PMID: 31274243 DOI: 10.1111/ijpo.12562]

8 **Vandyousefi S**, Whaley SE, Widen EM, Asigbee FM, Landry MJ, Ghaddar R, Davis JN. Association of breastfeeding and early exposure to sugar-sweetened beverages with obesity prevalence in offspring born to mothers with and without gestational diabetes mellitus. *Pediatr Obes* 2019; **14**: e12569 [PMID: 31389196 DOI: 10.1111/ijpo.12569]

9 **Li P**, Yin J, Zhu Y, Li S, Chen S, Sun T, Shan Z, Wang J, Shang Q, Li X, Yang W, Liu L. Association between plasma concentration of copper and gestational diabetes mellitus. *Clin Nutr* 2019; **38**: 2922-2927 [PMID: 30661907 DOI: 10.1016/j.clnu.2018.12.032]

10 **Vitacolonna E**, Succurro E, Lapolla A, Scavini M, Bonomo M, Di Cianni G, Di Benedetto A, Napoli A, Tumminia A, Festa C, Lencioni C, Torlone E, Sesti G, Mannino D, Purrello F. Guidelines for the screening and diagnosis of gestational diabetes in Italy from 2010 to 2019: critical issues and the potential for improvement. *Acta Diabetol* 2019; **56**: 1159-1167 [PMID: 31396699 DOI: 10.1007/s00592-019-01397-4]

11 **Bettencourt-Silva R**, Neves JS, Ferreira MJ, Souteiro P, Belo S, Oliveira AI, Carvalho D, Namora G, Montenegro N, Queirós J. Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study. *Endocrine* 2019; **66**: 192-200 [PMID: 31401725 DOI: 10.1007/s12020-019-02043-3]

12 **de Sousa RAL**, de Lima EV, da Silva TP, de Souza RV, Figueiredo CP, Passos GF, Clarke JR. Late Cognitive Consequences of Gestational Diabetes to the Offspring, in a New Mouse Model. *Mol Neurobiol* 2019; **56**: 7754-7764 [PMID: 31115777 DOI: 10.1007/s12035-019-1624-0]

13 **Kouroglou E**, Anagnostis P, Daponte A, Bargiota A. Vitamin B12 insufficiency is associated with increased risk of gestational diabetes mellitus: a systematic review and meta-analysis. *Endocrine* 2019; **66**: 149-156 [PMID: 31463884 DOI: 10.1007/s12020-019-02053-1]

14 **Prentice PM**, Olga L, Petry CJ, Simmons D, Murphy HR, Hughes IA, Acerini CL, Ong KK, Dunger DB. Reduced size at birth and persisting reductions in adiposity in recent, compared with earlier, cohorts of infants born to mothers with gestational diabetes mellitus. *Diabetologia* 2019; **62**: 1977-1987 [PMID: 31396660 DOI: 10.1007/s00125-019-4970-6]

15 **Pergialiotis V**, Bellos I, Hatziagelaki E, Antsaklis A, Loutradis D, Daskalakis G. Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis. *Am J Obstet Gynecol* 2019; **221**: 429-436.e5 [PMID: 31132340 DOI: 10.1016/j.ajog.2019.05.033]

16 **Iwama N**, Sugiyama T, Metoki H, Kusaka H, Yaegashi N, Sagawa N, Hiramatsu Y, Toyoda N; JAGS Group. Difference in the prevalence of gestational diabetes mellitus according to gestational age at 75-g oral glucose tolerance test in Japan: The Japan Assessment of Gestational Diabetes Mellitus Screening trial. *J Diabetes Investig* 2019; **10**: 1576-1585 [PMID: 30897272 DOI: 10.1111/jdi.13044]

17 **Benhalima K**, Van Crombrugge P, Moyson C, Verhaeghe J, Vandeginste S, Verlaenen H, Vercammen C, Maes T, Dufraimont E, De Block C, Jacquemyn Y, Mekahli F, De Clippel K, Van Den Bruel A, Loccufier A, Laenen A, Minschart C, Devlieger R, Mathieu C. Characteristics and pregnancy outcomes across gestational diabetes mellitus subtypes based on insulin resistance. *Diabetologia* 2019; **62**: 2118-2128 [PMID: 31338546 DOI: 10.1007/s00125-019-4961-7]

18 **Hill AV**, Menon R, Perez-Patron M, Carrillo G, Xu X, Taylor BD. High-mobility group box 1 at the time of parturition in women with gestational diabetes mellitus. *Am J Reprod Immunol* 2019; **82**: e13175 [PMID: 31353785 DOI: 10.1111/aji.13175]

19 **Bogdanet D**, Reddin C, Macken E, Griffin TP, Fhelelboom N, Biesty L, Thangaratinam S, Dempsey E, Crowther C, Galjaard S, Maresh M, Loeken MR, Napoli A, Anastasiou E, Noctor E, de Valk HW, van Poppel MNM, Agostini A, Clarson C, Egan AM, O'Shea PM, Devane D, Dunne FP. Follow-up at 1 year and beyond of women with gestational diabetes treated with insulin and/or oral glucose-lowering agents: a core outcome set using a Delphi survey. *Diabetologia* 2019; **62**: 2007-2016 [PMID: 31273408 DOI: 10.1007/s00125-019-4935-9]

20 **Anderlová K**, Cinkajzlová A, Šimják P, Kloučková J, Kratochvílová H, Lacinová Z, Kaválková P, Krejčí H, Mráz M, Pařízek A, Haluzík M, Kršek M. Insulin-like growth factor axis in pregnancy and gestational diabetes mellitus. *Physiol Res* 2019; **68**: 807-816 [PMID: 31424259 DOI: 10.33549/physiolres.934093]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by Institutional Review Board of The Second Affiliated Hospital of Hainan Medical College.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** All authors declare they have no conflicts of interest.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** September 1, 2020

**First decision:** September 13, 2020

**Article in press:** October 1, 2020

**Specialty type:** Obstetrics and gynecology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** LaRue S, Mohsen MM **S-Editor:** Wang JL **L-Editor:** Filipodia **P-Editor:** Xing YX

**Table 1 The comparison of levels of osteoprotegerin, interleukin-1β and hepatocyte growth factor between the two groups**

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | **OPG, pmol/L** | **IL-1β, ng/L** | **HGF** |
| Observation group | 1.94 ± 0.09 | 145.65 ± 9.45 | 5.65 ± 1.65 |
| Control group | 2.24 ± 0.14 | 45.65 ± 6.45 | 11.65 ± 2.56 |
| *t* | 11.957 | 57.976 | 13.069 |
| *P* value | 0.001 | 0.001 | 0.001 |

HGF: Hepatocyte growth factor; IL-1β: Interleukin-1β; OPG: Osteoprotegerin.

**Table 2 Correlation between gestational diabetes mellitus and gestational hypertension and osteoprotegerin, interleukin-1β and hepatocyte growth factor**

|  |  |
| --- | --- |
| **Indicators** | **GDM and gestational hypertension** |
| ***r*** | ***P* value** |
| OPG | -0.556 | < 0.05 |
| IL-1β | 0.456 | < 0.05 |
| HGF | -0.659 | < 0.05 |

GDM: Gestational diabetes mellitus; HGF: Hepatocyte growth factor; IL-1β: Interleukin-1β; OPG: Osteoprotegerin.